MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation.

By N. Felli, L. Fontana, E. Pelosi, R. Botta, D. Bonci, F. Facchiano, F. Liuzzi, V. Lulli, O. Morsilli, Simona Santoro and 6 more. Proceedings of the National Academy of Sciences of the United States of America, 2005

795 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/5631e50fd39d9c7a54dec2bb5e5a016f8402c8b5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Physiological and pathological roles for microRNAs in the immune system (2010, background): “miR-221 and miR-222 were also shown to inhibit KIT expression by stem and progenitor cells, leading to impaired cell proliferation and engraftment potentia”
MicroRNAs: new regulators of immune cell development and function (2008, background): “In addition, miR-221 and miR-222 are downregulated during erythropoiesis, thus relieving repression of their target, which encodes the stem cell factor receptor c-Ki”
MicroRNAs: key regulators of stem cells (2009, background): “Another mechanism that prevents erythropoiesis involves miR-221 and miR-222, which block erythropoiesis by targeting KIT (also known as CD117 ), a cytokine receptor that is expressed on the surface of haematopoietic stem cell”
Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways (2008, positive): “Interestingly, miR-221 can inhibit c-Kit expression while miR-10a inhibits the Homeobox gene Hox-A1 and both c-Kit and Hox-A1 have roles in hematopoiesis and T cell development [20,22,69].”
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma (2007, background): “Similarly, it should be possible to correct miRNAs downregulated in tumors using miRNA expression strategies such as viral delivery systems (Felli et al., 2005).”
Causes and consequences of microRNA dysregulation in cancer (2009, background): “pl?acc=MI0000299">miR-222 target an oncogene, KIT , and inhibit the growth of erythroblastic leukaemi”
OncomiRs: the discovery and progress of microRNAs in cancers (2007, background): “The decline of miR-221 and miR-222 during exponential erythropoietic growth unblocked Kit protein production at mRNA level, thus leading to expansion of early erythroblasts [26].”
MicroRNA-133 controls cardiac hypertrophy (2007, background): “MiRNAs are involved in a variety of basic biological processes, for example, cell proliferation and apoptosi”
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma (2008, background): “Third, miR-221 is selectively upregulated in several human cancers and evidences supporting its role in carcinogenesis and increased cell growth have been reported (Felli et al., 2005; Galardi et al., 2007; Gillies and Lorimer, 2007; Le Sage et al., 2007; Visone et al., 2007).”
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death (2008, background): “One such observation implicates miR-221 and miR-222 in maintaining hematopoietic stem cells by preventing the formation of early erythroblasts by directly targeting the receptor c-kit (Felli et al., 2005).”